Marilin Koch

476 total citations
15 papers, 316 citations indexed

About

Marilin Koch is a scholar working on Immunology, Genetics and Oncology. According to data from OpenAlex, Marilin Koch has authored 15 papers receiving a total of 316 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Immunology, 6 papers in Genetics and 5 papers in Oncology. Recurrent topics in Marilin Koch's work include Glioma Diagnosis and Treatment (6 papers), Virus-based gene therapy research (4 papers) and CAR-T cell therapy research (4 papers). Marilin Koch is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Virus-based gene therapy research (4 papers) and CAR-T cell therapy research (4 papers). Marilin Koch collaborates with scholars based in Germany, United States and Belgium. Marilin Koch's co-authors include Sean Lawler, E. Antonio Chiocca, Ghazaleh Tabatabai, Alexander Grimm, Natalie Winter, Nele Dammeier, Tim W. Rattay, Eva Auffenberg, Florian Härtig and Hubertus Axer and has published in prestigious journals such as Clinical Neurophysiology, The Oncologist and Cancers.

In The Last Decade

Marilin Koch

14 papers receiving 312 citations

Peers

Countries citing papers authored by Marilin Koch

Since Specialization

Citations

This map shows the geographic impact of Marilin Koch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marilin Koch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marilin Koch more than expected).

Fields of papers citing papers by Marilin Koch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marilin Koch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marilin Koch. The network helps show where Marilin Koch may publish in the future.

Co-authorship network of co-authors of Marilin Koch

This figure shows the co-authorship network connecting the top 25 collaborators of Marilin Koch. A scholar is included among the top collaborators of Marilin Koch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marilin Koch. Marilin Koch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	PPRX-1701, a nanoparticle formulation of 6′-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models 2023 ·Cell Reports Medicine ·Mykola Zdioruk, (unknown), Michal O. Nowicki, Katherine E. Manz, Kurt D. Pennell, Marilin Koch, (unknown), Bin Wu, (unknown), Yuji Takeda, (unknown), Raziye Piranlioglu, Alexander Ling, E. Antonio Chiocca, Sean Lawler	8
2	Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models 2023 ·Frontiers in Medicine ·Marilin Koch, Mykola Zdioruk, Michal O. Nowicki, (unknown), Zachary T. Herbert, Francesca Barone, Paul P. Tak, E. Antonio Chiocca, Ghazaleh Tabatabai, Sean Lawler	4
3	Self-assembled ruthenium and osmium nanosystems display a potent anticancer profile by interfering with metabolic activity 2022 ·Inorganic Chemistry Frontiers ·(unknown), (unknown), (unknown), (unknown), (unknown), Marilin Koch, Michal O. Nowicki, Véronique Mathieu, Justin R. Pritchard, Samuel G. Awuah, Sean Lawler, F. Meyer, François Dufrasne, Gilles Berger	5
4	Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma 2022 ·Molecular Therapy — Oncolytics ·Marilin Koch, Mykola Zdioruk, Michal O. Nowicki, (unknown), Estuardo Aguilar-Córdova, Laura K. Aguilar, Brian W. Guzik, Francesca Barone, Paul P. Tak, Katharina Schregel, (unknown), James A. Lederer, E. Antonio Chiocca, Ghazaleh Tabatabai, Sean Lawler	6
5	Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models 2022 ·Journal for ImmunoTherapy of Cancer ·Marilin Koch, Mykola Zdioruk, Michal O. Nowicki, (unknown), (unknown), Laura K. Aguilar, Brian W. Guzik, Francesca Barone, Paul P. Tak, Ghazaleh Tabatabai, James A. Lederer, E. Antonio Chiocca, Sean Lawler	17
6	TAMI-34. TARGETING CSF1R AND PD1 IN EXPERIMENTAL GLIOMA 2021 ·Neuro-Oncology ·(unknown), Justyna M. Przystal, (unknown), (unknown), (unknown), (unknown), (unknown), Carola H. Ries, Martina Schmittnaegel, (unknown), Marilin Koch, Jens Schittenhelm, Marcos Tatagiba, Christian Schmees, Susanne Beck, Ghazaleh Tabatabai	1
7	Targeting CSF1R Alone or in Combination with PD1 in Experimental Glioma 2021 ·Cancers ·Justyna M. Przystal, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Carola H. Ries, Martina Schmittnaegel, (unknown), Marilin Koch, Jens Schittenhelm, Marcos Tatagiba, Christian Schmees, Susanne Beck, Ghazaleh Tabatabai	39
8	Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition 2020 ·Neuro-Oncology Advances ·Marilin Koch, Stefan Czemmel, (unknown), (unknown), (unknown), Justyna M. Przystal, Parameswari Govindarajan, (unknown), Manfred Neumann, Patrizia Rizzu, Stefan Zwirner, (unknown), Lars Zender, (unknown), Marcos Tatagiba, Olivier Raineteau, Peter Heutink, Sven Nahnsen, Ghazaleh Tabatabai	2
9	HSV-1 Oncolytic Viruses from Bench to Bedside: An Overview of Current Clinical Trials 2020 ·Cancers ·Marilin Koch, Sean Lawler, E. Antonio Chiocca	43
10	IMMU-46. EXAMINATION OF THE EFFECTS OF DEXAMETHASONE ON THE EFFICACY OF IMMUNOTHERAPY IN GLIOMA USING GENE-MEDIATED CYTOTOXIC IMMUNOTHERAPY 2019 ·Neuro-Oncology ·Marilin Koch, Mykola Zdioruk, Michal O. Nowicki, (unknown), Laura K. Aguilar, Brian W. Guzik, E. Antonio Chiocca, Sean Lawler	0
11	Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy—a Prospective Follow-Up 2018 ·Neurotherapeutics ·Florian Härtig, (unknown), Nele Dammeier, (unknown), Bianka Heiling, Hubertus Axer, Bernhard F. Décard, Eva Auffenberg, Marilin Koch, Tim W. Rattay, Markus Krumbholz, Antje Bornemann, Holger Lerche, Natalie Winter, Alexander Grimm	70
12	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma 2018 ·Molecular Therapy — Oncolytics ·(unknown), (unknown), Michael Ghosh, Marius Cosmin Codrea, (unknown), (unknown), Marcos Tatagiba, Marilin Koch, Ulrich M. Lauer, Sven Nahnsen, Hans‐Georg Rammensee, Michael D. Mühlebach, Stefan Stevanović, Ghazaleh Tabatabai	43
13	A look inside the nerve – Morphology of nerve fascicles in healthy controls and patients with polyneuropathy 2017 ·Clinical Neurophysiology ·Alexander Grimm, Natalie Winter, Tim W. Rattay, Florian Härtig, Nele Dammeier, Eva Auffenberg, Marilin Koch, Hubertus Axer	41
14	Low FoxG1 and high Olig‐2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)‐mutant gliomas 2017 ·Neuropathology and Applied Neurobiology ·Sarah K. Schäfer, Felix Behling, Marco Skardelly, Marilin Koch, Ingo Ott, Frank Paulsen, Ghazaleh Tabatabai, Jens Schittenhelm	12
15	Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma 2017 ·The Oncologist ·Marco Skardelly, (unknown), (unknown), Susan Noell, Felix Behling, Guilherme Lepski, (unknown), Marilin Koch, Jens Schittenhelm, Sotirios Bisdas, Aline Naumann, Frank Paulsen, Daniel Zips, Ulrike von Hehn, Rainer Ritz, Marcos Tatagiba, Ghazaleh Tabatabai	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact